Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Retained Earnings (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Retained Earnings for 8 consecutive years, with -$4.2 million as the latest value for Q1 2026.

  • For Q1 2026, Retained Earnings rose 99.49% year-over-year to -$4.2 million; the TTM value through Mar 2026 reached -$4.2 million, up 99.49%, while the annual FY2025 figure was $1.8 million, 221.21% up from the prior year.
  • Retained Earnings hit -$4.2 million in Q1 2026 for Kymera Therapeutics, down from $1.8 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $1.9 million in Q3 2024 and bottomed at -$979.0 million in Q3 2025.
  • Average Retained Earnings over 5 years is -$262.0 million, with a median of -$4.2 million recorded in 2026.
  • On a YoY basis, Retained Earnings climbed as much as 221.21% in 2025 and fell as far as 50798.08% in 2025.
  • Kymera Therapeutics' Retained Earnings stood at -$4.9 million in 2022, then surged by 88.85% to -$552000.0 in 2023, then plummeted by 169.02% to -$1.5 million in 2024, then soared by 221.21% to $1.8 million in 2025, then plummeted by 333.0% to -$4.2 million in 2026.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$4.2 million, $1.8 million, and -$979.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.